Animal study · Supplements / medicine · 3 Sept 2026
Diabetes drug metformin could be repurposed to help slow aging mechanisms
Source: Medical Xpress
What the research found
Commentary (review). A Hamad Bin Khalifa University review in Aging (DOI 10.18632/aging.206407) gathers cell, animal, and human studies on metformin and biological aging. The authors describe AMPK activation, autophagy, DNA-methylation stability, and microbiome shifts. Animal data include longer C. elegans lifespan and mixed mouse lifespan gains; human signals are mostly observational in people with diabetes, and a widely cited survival paper has been hard to reproduce. The planned TAME trial is meant to test whether metformin delays age-related disease in people without diabetes. Metformin remains a prescription medicine for type 2 diabetes. Off-label longevity use is clinician-only. This is not medical advice and not a reason to start, stop, or replace any drug.
Evidence level: Animal study. Results in animals or cells often don't carry over to people.
Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34